A core challenge in the analysis of experimental data is that the impact of some intervention is often not entirely captured by a single, well-defined outcome . Instead there may be a large number of outcome variables that are potentially affected and of interest. In this paper, we propose a data-driven approach rooted in machine learning to the problem of testing effects on such groups of outcome variables. It is based on two simple observations. First, the 'false-positive' problem that a group of outcomes is similar to the concern of 'over-fitting, ' which has been the focus of a large literature in statistics and computer science. We can thus leverage sample-splitting methods from the machine-learning playbook that are designed to control over-fitting to ensure that statistical models express generalizable insights about treatment effects. The second simple observation is that the question whether treatment affects a group of variables is equivalent to the question whether treatment is predictable from these variables better than some trivial benchmark (provided treatment is assigned randomly) . This formulation allows us to leverage data-driven predictors from the machine-learning literature to flexibly mine for effects, rather than rely on more rigid approaches like multiple-testing corrections and pre-analysis plans. We formulate a specific methodology and present three kinds of results: first, our test is exactly sized for the null hypothesis of no effect; second, a specific version is asymptotically equivalent to a benchmark joint Wald test in a linear regression; and third, this methodology can guide inference on where an intervention has effects. Finally, we argue that our approach can naturally deal with typical features of real-world experiments, and be adapted to baseline balance checks .
In this paper we present tools for applied researchers that re-purpose off-the-shelf methods from the computer-science field of machine learning to create a "discovery engine" for data from randomized controlled trials (RCTs). The applied problem we seek to solve is that economists invest vast resources into carrying out RCTs, including the collection of a rich set of candidate outcome measures. But given concerns about inference in the presence of multiple testing, economists usually wind up exploring just a small subset of the hypotheses that the available data could be used to test. This prevents us from extracting as much information as possible from each RCT, which in turn impairs our ability to develop new theories or strengthen the design of policy interventions. Our proposed solution combines the basic intuition of reverse regression, where the dependent variable of interest now becomes treatment assignment itself, with methods from machine learning that use the data themselves to flexibly identify whether there is any function of the outcomes that predicts (or has signal about) treatment group status. This leads to correctly-sized tests with appropriate p-values, which also have the important virtue of being easy to implement in practice. One open challenge that remains with our work is how to meaningfully interpret the signal that these methods find .
R
A core challenge in the analysis of experimental data is that the impact of some intervention is often not entirely captured by a single, well-defined outcome . Instead there may be a large number of outcome variables that are potentially affected and of interest. In this paper, we propose a data-driven approach rooted in machine learning to the problem of testing effects on such groups of outcome variables. It is based on two simple observations. First, the 'false-positive' problem that a group of outcomes is similar to the concern of 'over-fitting, ' which has been the focus of a large literature in statistics and computer science. We can thus leverage sample-splitting methods from the machine-learning playbook that are designed to control over-fitting to ensure that statistical models express generalizable insights about treatment effects. The second simple observation is that the question whether treatment affects a group of variables is equivalent to the question whether treatment is predictable from these variables better than some trivial benchmark (provided treatment is assigned randomly) . This formulation allows us to leverage data-driven predictors from the machine-learning literature to flexibly mine for effects, rather than rely on more rigid approaches like multiple-testing corrections and pre-analysis plans. We formulate a specific methodology and present three kinds of results: first, our test is exactly sized for the null hypothesis of no effect; second, a specific version is asymptotically equivalent to a benchmark joint Wald test in a linear regression; and third, this methodology can guide inference on where an intervention has effects. Finally, we argue that our approach can naturally deal with typical features of real-world experiments, and be adapted to baseline balance checks
In this paper we present tools for applied researchers that re-purpose off-the-shelf methods from the computer-science field of machine learning to create a "discovery engine" for data from randomized controlled trials (RCTs). The applied problem we seek to solve is that economists invest vast resources into carrying out RCTs, including the collection of a rich set of candidate outcome measures. But given concerns about inference in the presence of multiple testing, economists usually wind up exploring just a small subset of the hypotheses that the available data could be used to test. This prevents us from extracting as much information as possible from each RCT, which in turn impairs our ability to develop new theories or strengthen the design of policy interventions. Our proposed solution combines the basic intuition of reverse regression, where the dependent variable of interest now becomes treatment assignment itself, with methods from machine learning that use the data themselves to flexibly identify whether there is any function of the outcomes that predicts (or has signal about) treatment group status. This leads to correctly-sized tests with appropriate p-values, which also have the important virtue of being easy to implement in practice. One open challenge that remains with our work is how to meaningfully interpret the signal that these methods find